Due to health issues, this site is no longer maintained and will be shut down shortly.

SPHRY Starpharma Holdings Limited Sponsored ADRs

Starpharma Holdings Limited engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company focuses on the development of VivaGel, which has completed Phase III clinical trials for the management and prevention of bacterial vaginosis, and as a condom coating for the prevention of sexually transmitted infections, as well as VivaGel condom, an antiviral condom. It also develops DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase II clinical trials, DEP cabazitaxel that is in Phase 1/2 clinical trial, and DEP irinotecan that is in phase 1/2 clinical trials for the treatment of solid tumors. The company was founded in 1996 and is headquartered in Abbotsford, Australia. This is an ADR of a company whose stock trades outside of the U.S. as the symbol AT:SPL.

This security is traded over-the-counter, or OTC. We don't always have accurate pricing data on OTC stocks.

$3.16    OTCQX
As of 03/23/2023     OTCMarkets


Security Information
Category1:  US Equity
Category2:  ADRs
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  Australia
Country of incorporation:  Australia
IPO date:  12/29/2004
Outstanding shares:  40,892,007
Average volume:  585
Market cap:   $129,271,902
Current dividend yield:  0.00%
Sedol:      
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   0.00
PS ratio:   0.00
Return on equity:   0.00%
Net income %:   0.00%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy